GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » Debt-to-Equity

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Debt-to-Equity : 0.15 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co Debt-to-Equity?

China Resourcesnjiu Medical & Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,098 Mil. China Resourcesnjiu Medical & Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,893 Mil. China Resourcesnjiu Medical & Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥20,346 Mil. China Resourcesnjiu Medical & Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SZSE:000999' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.05   Max: 0.19
Current: 0.15

During the past 13 years, the highest Debt-to-Equity Ratio of China Resourcesnjiu Medical & Pharmaceutical Co was 0.19. The lowest was 0.00. And the median was 0.05.

SZSE:000999's Debt-to-Equity is ranked better than
65.1% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs SZSE:000999: 0.15

China Resourcesnjiu Medical & Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co Debt-to-Equity Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.02 0.02 0.16

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.19 0.16 0.16 0.15

Competitive Comparison of China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity falls into.



China Resourcesnjiu Medical & Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China Resourcesnjiu Medical & Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

China Resourcesnjiu Medical & Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resourcesnjiu Medical & Pharmaceutical Co  (SZSE:000999) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


China Resourcesnjiu Medical & Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Traded in Other Exchanges
N/A
Address
High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines